CN110015996B - Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside - Google Patents
Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside Download PDFInfo
- Publication number
- CN110015996B CN110015996B CN201910374991.2A CN201910374991A CN110015996B CN 110015996 B CN110015996 B CN 110015996B CN 201910374991 A CN201910374991 A CN 201910374991A CN 110015996 B CN110015996 B CN 110015996B
- Authority
- CN
- China
- Prior art keywords
- substituted
- reaction
- spirocyclic
- synthesizing
- carbocyclic nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Saccharide Compounds (AREA)
Abstract
本发明公开了一种合成2′‑螺环基取代的三元碳环核苷的方法,属于有机化学技术领域。α‑嘧啶取代的丙烯酸酯和α‑氯代环烷酮为原料,通过迈克反应启动的环丙环化反应,合成了系列结构新型螺环核苷。本发明采用原料简单易得,在合成过程中避免了以往方法中步骤繁多、产率低和普适性差的缺点。通过该方法合成的螺环嘧啶核苷产率高达84%,且产物结构丰富。The invention discloses a method for synthesizing a 2'-spirocyclic group-substituted three-membered carbocyclic nucleoside, and belongs to the technical field of organic chemistry. Using α-pyrimidine-substituted acrylate and α-chlorocycloalkanone as raw materials, a series of new spiro nucleosides were synthesized through cyclopropane cyclization initiated by Mike's reaction. The method of the invention adopts simple and easy-to-obtain raw materials, and avoids the disadvantages of numerous steps, low yield and poor universality in the previous method in the synthesis process. The yield of spirocyclic pyrimidine nucleosides synthesized by this method is as high as 84%, and the product structure is rich.
Description
技术领域technical field
本发明涉及螺环核苷的合成方法,具体涉及采用环丙环化反应合成2′-螺环基取代三元碳环核苷的方法,属于有机化学技术领域。The invention relates to a method for synthesizing spirocyclic nucleosides, in particular to a method for synthesizing 2'-spirocyclic group-substituted three-membered carbocyclic nucleosides by cyclopropane cyclization, and belongs to the technical field of organic chemistry.
背景技术Background technique
螺环核苷大多都属于构象限制核苷,其分子构象组成较为单一。底物与酶进行结合前,酶活性中心构象会先根据底物构象发生变化,接着再与底物契合形成活性络合物,构象单一的底物会更有利于酶活性中心构象转化,因此发展构象限制核苷相对于非构象限制核苷药物具有一定的优势。目前,公开报道的合成螺环核苷方法步骤繁琐且普适性差,主要是在糖环4′位引入螺环,典型的代表性合成路线如下:Most of the spiro nucleosides are conformationally restricted nucleosides, and their molecular conformation is relatively simple. Before the substrate is combined with the enzyme, the conformation of the active center of the enzyme will first change according to the conformation of the substrate, and then it will fit with the substrate to form an active complex. Conformation-restricted nucleosides have certain advantages over non-conformation-restricted nucleoside drugs. At present, the publicly reported methods for synthesizing spirocyclic nucleosides are cumbersome and poorly universal, mainly introducing a spiro ring at the 4' position of the sugar ring. A typical representative synthetic route is as follows:
1、螺环嘧啶核苷G和F的合成,反应方程式如下:1, the synthesis of spirocyclic pyrimidine nucleosides G and F, the reaction equation is as follows:
该方法合成步骤长,C-N键缩合时需要用到昂贵的金属钯催化,所得产物为两种构型的异构体混合物,分离比较困难。The method has long synthesis steps, expensive metal palladium catalysis is required for the condensation of C-N bonds, and the obtained product is a mixture of isomers of two configurations, which is difficult to separate.
2、螺环嘧啶核苷D的合成,反应方程式如下:2, the synthesis of spirocyclic pyrimidine nucleoside D, the reaction equation is as follows:
该方法合成步骤长,底物普适性差,先是采用邻溴苯胺缩合,最终采用n-Bu3SnH方法自由基脱溴,增加了不必要的反应。This method has long synthesis steps and poor substrate universality. First, o-bromoaniline is used for condensation, and finally, the n-Bu 3 SnH method is used for free radical debromination, which increases unnecessary reactions.
鉴于螺环核苷作为构象限制核苷的重要组成部分,因此寻找简单高效合成螺环核苷的方法仍非常必要。Given that spiro nucleosides are an important part of conformationally restricted nucleosides, it is still necessary to find a simple and efficient method for the synthesis of spiro nucleosides.
发明内容SUMMARY OF THE INVENTION
为了克服上述缺陷,本发明提供了一种合成2′-螺环基取代三元碳环核苷的方法。以α-嘧啶取代丙烯酸酯和α-氯代环烷酮为原料,在无机碱作用下通过迈克反应启动环丙环化反应,合成了系列新型螺环核苷化合物。该方法为合成螺环核苷化合物提供了一种简便、廉价、高效的途径。In order to overcome the above-mentioned defects, the present invention provides a method for synthesizing 2'-spirocyclyl-substituted three-membered carbocyclic nucleosides. Using α-pyrimidine substituted acrylate and α-chlorocycloalkanone as raw materials, a series of new spirocyclic nucleoside compounds were synthesized by Mike reaction initiating cyclopropane cyclization under the action of inorganic base. This method provides a simple, cheap and efficient way for the synthesis of spirocyclic nucleoside compounds.
一种合成2′-螺环基取代三元碳环核苷的方法,其特征在于,包括如下操作:以α-嘧啶取代丙烯酸酯1与α-氯代环烷酮2为原料,在碱作用下,有机溶剂中反应得到螺环嘧啶核苷3。反应方程式如下:A method for synthesizing 2'-spirocyclyl-substituted three-membered carbocyclic nucleosides, comprising the following operations: using α-pyrimidine-substituted acrylate 1 and α-chlorocycloalkanone 2 as raw materials, and under the action of a base Under the following conditions, the spirocyclic pyrimidine nucleoside 3 is obtained by the reaction in an organic solvent. The reaction equation is as follows:
其中,R1选自氢、C1-C6烷基、烷氧基;R2选自C1-C4烷基、苄基、苯基;R3选自苯甲酰基和叔丁氧羰基;具体而言,R1选自甲基、乙基、氢、卤素、甲氧基或三氟甲基;R2选自甲基、乙基、叔丁基、苯基或苄基。Wherein, R 1 is selected from hydrogen, C1-C6 alkyl, alkoxy; R 2 is selected from C1-C4 alkyl, benzyl, phenyl; R 3 is selected from benzoyl and tert-butoxycarbonyl; specifically , R 1 is selected from methyl, ethyl, hydrogen, halogen, methoxy or trifluoromethyl; R 2 is selected from methyl, ethyl, tert-butyl, phenyl or benzyl.
进一步地,在上述技术方案中,所述α-嘧啶取代丙烯酸酯1、α-氯代环烷酮2与碱摩尔比为1:1.2-1.5:1.2-2.0,优选摩尔比为1:1.5:1.5。Further, in the above technical scheme, the molar ratio of the α-pyrimidine substituted acrylate 1, α-chlorocycloalkanone 2 and the base is 1:1.2-1.5:1.2-2.0, and the preferred molar ratio is 1:1.5: 1.5.
进一步地,在上述技术方案中,所述溶剂选自乙腈、甲醇、二氯甲烷、四氢呋喃、甲苯或二氧六环。Further, in the above technical solution, the solvent is selected from acetonitrile, methanol, dichloromethane, tetrahydrofuran, toluene or dioxane.
进一步地,在上述技术方案中,所述碱选自:碳酸钠、碳酸钾、碳酸铯、乙酸钠、DBU、叔丁醇钠或叔丁醇钾。优选碳酸钾、DBU、碳酸铯或叔丁醇钾。Further, in the above technical scheme, the base is selected from: sodium carbonate, potassium carbonate, cesium carbonate, sodium acetate, DBU, sodium tert-butoxide or potassium tert-butoxide. Potassium carbonate, DBU, cesium carbonate or potassium tert-butoxide are preferred.
进一步地,在上述技术方案中,反应温度选自-30℃到50℃。Further, in the above technical solution, the reaction temperature is selected from -30°C to 50°C.
进一步地,在上述技术方案中,整个反应过程无需惰性气体保护。Further, in the above technical solution, the entire reaction process does not require protection of inert gas.
进一步地,在上述技术方案中,螺环嘧啶产物3进一步衍生反应可以得到不同类型的衍生产物4或5。反应方程式如下:Further, in the above technical scheme, the spirocyclic pyrimidine product 3 is further derivatized to obtain different types of derivative products 4 or 5. The reaction equation is as follows:
其中,还原剂选自硼氢化钠或四氢铝锂;脱保护反应选用氨/甲醇或三氟乙酸。具体而言,还原反应溶剂选自二氯甲烷和甲醇混合溶剂下进行,优选体积比例二氯甲烷:甲醇=2:1。氨/甲醇溶液用于脱除R3为苯甲酰基保护,三氟乙酸用用于脱除R3为叔丁氧羰基保护。Wherein, the reducing agent is selected from sodium borohydride or lithium aluminum tetrahydrogen; the deprotection reaction is selected from ammonia/methanol or trifluoroacetic acid. Specifically, the reduction reaction solvent is selected from a mixed solvent of dichloromethane and methanol, and the volume ratio is preferably dichloromethane:methanol=2:1. Ammonia/methanol solution was used to remove R 3 for benzoyl protection, and trifluoroacetic acid was used to remove R 3 for tert-butoxycarbonyl protection.
发明有益效果:Invention Beneficial Effects:
该方法为合成螺环核苷化合物提供了一种简便、廉价、高效的途径。采用的原料简单易得,在合成过程中避免了以往方法中步骤繁多、产率低和普适性差的缺点。通过该方法合成的螺环嘧啶核苷产率高达84%,且产物结构丰富。This method provides a simple, cheap and efficient way for the synthesis of spirocyclic nucleoside compounds. The raw materials used are simple and easy to obtain, and in the synthesis process, the disadvantages of many steps, low yield and poor universality in the previous method are avoided. The yield of spirocyclic pyrimidine nucleosides synthesized by this method is as high as 84%, and the product structure is rich.
具体实施方式Detailed ways
实施例1Example 1
a除非特别说明,反应的步骤如下:1a(0.1mmol),2a(1.5equiv),碱(1.5equiv)在空气中反应5小时。b分离收率c叔丁醇钾(1.2equiv)d叔丁醇钾(2.0equiv)e1h f0.5h。 a Unless otherwise specified, the reaction steps are as follows: 1a (0.1 mmol), 2a (1.5 equiv), and base (1.5 equiv) were reacted in air for 5 hours. b Isolated yield c Potassium tert-butoxide (1.2 equiv) d Potassium tert-butoxide (2.0 equiv) e 1h f 0.5h.
在反应条件的筛选过程中,首先考察了碱对该反应的影响(entries 1-6)。其次对溶剂和温度进行了考察,通过对产率进行对比,最终确定了叔丁醇钾为最优碱,乙腈为最优溶剂,-20℃为最佳温度。During the screening of reaction conditions, the effect of bases on the reaction was first investigated (entries 1-6). Secondly, the solvent and temperature were investigated. By comparing the yields, it was finally determined that potassium tert-butoxide was the optimal base, acetonitrile was the optimal solvent, and -20°C was the optimal temperature.
典型的反应条件操作:Typical reaction conditions for operation:
在反应瓶内,将α-嘧啶取代丙烯酸甲酯1a(0.1mmol)和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应时间为0.5h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3aa,收率83%。In a reaction flask, α-pyrimidine substituted methyl acrylate 1a (0.1 mmol) and 1.5 eq (0.15 mmol) potassium tert-butoxide were dissolved in 1 mL of acetonitrile, and placed at -20 °C for 10 minutes with stirring and cooling, and then α-chloro Substituted cycloalkanone 2a (0.15mmol) was added to the reaction solution for reaction, and the reaction time was 0.5h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3aa was obtained by column chromatography with a yield of 83%.
3aa:White solid,m.p.227.2-232.5℃;33mg,83%yield;3aa: White solid, m.p. 227.2-232.5℃; 33mg, 83% yield;
1H NMR(400MHz,CDCl3):7.90-7.88(d,J=8.0Hz,2H),7.62(d,J=7.6Hz,1H),7.48(t,J=8.0Hz,2H),7.06(d,J=3.2Hz,1H),3.77(s,3H),2.44(m,1H),2.36-2.27(m,1H),2.27-2.17(m,2H),2.08(m,2H),2.01-1.95(m,4H),1.89(s,1H).13C NMR(100MHz,CDCl3):212.1,167.7,139.4,135.0,131.5,130.7,129.1,111.5,77.3,53.6,50.4,42.6,38.9,28.5,26.2,20.2,12.7.HRMS(ESI-TOF):exact mass calcd for C21H20N2NaO6(M+Na)+requires m/z 419.1214,found m/z 419.1206. 1 H NMR (400 MHz, CDCl 3 ): 7.90-7.88 (d, J=8.0 Hz, 2H), 7.62 (d, J=7.6 Hz, 1H), 7.48 (t, J=8.0 Hz, 2H), 7.06 ( d, J=3.2Hz, 1H), 3.77(s, 3H), 2.44(m, 1H), 2.36-2.27(m, 1H), 2.27-2.17(m, 2H), 2.08(m, 2H), 2.01 -1.95(m, 4H), 1.89(s, 1H). 13 C NMR (100MHz, CDCl 3 ): 212.1, 167.7, 139.4, 135.0, 131.5, 130.7, 129.1, 111.5, 77.3, 53.6, 50.4, 42.6, 38.9 ,28.5,26.2,20.2,12.7.HRMS(ESI-TOF):exact mass calcd for C 21 H 20 N 2 NaO 6 (M+Na) + requires m/z 419.1214,found m/z 419.1206.
实施例2Example 2
在10mL真空管中,将α-(3-苯甲酰基-5-甲基)尿嘧啶取代丙烯酸乙酯1b和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应0.5h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3ba,收率85%。In a 10 mL vacuum tube, α-(3-benzoyl-5-methyl)uracil-substituted ethyl acrylate 1b and 1.5 eq (0.15 mmol) potassium tert-butoxide were dissolved in 1 mL of acetonitrile, and stirred at -20 °C After cooling for 10 minutes, α-chlorocycloalkanone 2a (0.15 mmol) was added to the reaction solution for reaction for 0.5 h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3ba was obtained by column chromatography with a yield of 85%.
实施例3Example 3
在10mL真空管中,将α-(3-苯甲酰基-5-甲基)尿嘧啶取代丙烯酸叔丁酯1c和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应0.5h。通过TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3ca,收率83%。In a 10 mL vacuum tube, dissolve α-(3-benzoyl-5-methyl)uracil-substituted tert-butyl acrylate 1c and 1.5 eq (0.15 mmol) potassium tert-butoxide in 1 mL of acetonitrile and place at -20°C After stirring and cooling for 10 minutes, α-chlorocycloalkanone 2a (0.15 mmol) was added to the reaction solution for reaction for 0.5 h. The reaction was monitored by TLC for completion, quenched with water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3ca was obtained by column chromatography with a yield of 83%.
实施例4Example 4
在10mL真空管中,将α-(3-苯甲酰基-5-甲基)尿嘧啶取代的丙烯酸苄酯1d和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应时间为0.5h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3da,收率83%。In a 10 mL vacuum tube, dissolve α-(3-benzoyl-5-methyl)uracil-substituted benzyl acrylate 1d and 1.5 eq (0.15 mmol) potassium tert-butoxide in 1 mL of acetonitrile and place at -20°C After stirring and cooling for 10 minutes, α-chlorocycloalkanone 2a (0.15 mmol) was added to the reaction solution for reaction, and the reaction time was 0.5 h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3da was obtained by column chromatography with a yield of 83%.
实施例5Example 5
在10mL真空管中,将α-(3-叔丁氧羰基-5-甲基)尿嘧啶取代丙烯酸甲酯1f和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应0.5h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3fa,收率79%。In a 10 mL vacuum tube, dissolve α-(3-tert-butoxycarbonyl-5-methyl)uracil substituted methyl acrylate 1f and 1.5 eq (0.15 mmol) potassium tert-butoxide in 1 mL of acetonitrile and place at -20°C After stirring and cooling for 10 minutes, α-chlorocycloalkanone 2a (0.15 mmol) was added to the reaction solution for reaction for 0.5 h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3fa was obtained by column chromatography with a yield of 79%.
3fa:White solid,m.p.180.0-185.4℃;31mg,79%yield;3fa: White solid, m.p.180.0-185.4℃; 31mg, 79% yield;
1H NMR(600MHz,CDCl3):6.94-6.92(m,1H),3.74(s,3H),2.65-2.44(m,2H),2.33-2.18(m,3H),2.03(d,J=4.8Hz,1H),1.93-1.92(m,3H),1.89(d,J=5.4Hz,1H),1.68(s,1H),1.56(s,9H).13C NMR(100MHz,CDCl3):211.2,167.8,147.7,139.0,111.1,86.5,53.6,50.6,42.4,38.8,28.6,27.5,26.3,20.2,12.7.HRMS(ESI-TOF):exact mass calcd forC19H24N2NaO7(M+Na)+requires m/z 415.1476,found m/z 415.1471. 1 H NMR (600 MHz, CDCl 3 ): 6.94-6.92 (m, 1H), 3.74 (s, 3H), 2.65-2.44 (m, 2H), 2.33-2.18 (m, 3H), 2.03 (d, J= 4.8Hz, 1H), 1.93-1.92(m, 3H), 1.89(d, J=5.4Hz, 1H), 1.68(s, 1H), 1.56(s, 9H). 13 C NMR (100MHz, CDCl 3 ) :211.2,167.8,147.7,139.0,111.1,86.5,53.6,50.6,42.4,38.8,28.6,27.5,26.3,20.2,12.7.HRMS(ESI-TOF):exact mass calcd forC 19 H 24 N 2 NaO 7 ( M+Na) + requires m/z 415.1476, found m/z 415.1471.
实施例6Example 6
在10mL真空管中,将α-(3-苯甲酰基-5-乙基)尿嘧啶取代丙烯酸甲酯1i和1.5eq(0.15mmol)的叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应0.5h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3ia,收率81%。In a 10 mL vacuum tube, dissolve α-(3-benzoyl-5-ethyl)uracil substituted methyl acrylate 1i and 1.5 eq (0.15 mmol) of potassium tert-butoxide in 1 mL of acetonitrile and place at -20°C After stirring and cooling for 10 minutes, α-chlorocycloalkanone 2a (0.15 mmol) was added to the reaction solution for reaction for 0.5 h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3ia was obtained by column chromatography with a yield of 81%.
3ia Colorless oil,33mg,81%yield;3ia Colorless oil, 33mg, 81% yield;
1H NMR(400MHz,CDCl3):7.88(d,J=7.6Hz,2H),7.61(d,J=7.2Hz,1H),7.47(d,J=7.6Hz,2H),6.98(s,1H),3.77(s,3H),2.47-2.37(m,3H),2.35-2.18(m,3H),2.14-2.08(m,2H),1.96(d,J=5.2Hz,1H),1.90-1.85(m,1H),1.17(t,J=7.2Hz,3H).13C NMR(100MHz,CDCl3):212.1,168.6,167.7,138.5,135.0,131.5,130.6,129.1,117.1,53.6,50.5,42.6,38.9,28.5,26.2,20.3,20.1,12.5.HRMS(ESI-TOF):exact mass calcd for C22H22N2NaO6(M+Na)+requires m/z 433.1370,found m/z 433.1365. 1 H NMR (400 MHz, CDCl 3 ): 7.88 (d, J=7.6 Hz, 2H), 7.61 (d, J=7.2 Hz, 1H), 7.47 (d, J=7.6 Hz, 2H), 6.98 (s, 1H), 3.77(s, 3H), 2.47-2.37(m, 3H), 2.35-2.18(m, 3H), 2.14-2.08(m, 2H), 1.96(d, J=5.2Hz, 1H), 1.90 -1.85 (m, 1H), 1.17 (t, J=7.2Hz, 3H). 13 C NMR (100 MHz, CDCl 3 ): 212.1, 168.6, 167.7, 138.5, 135.0, 131.5, 130.6, 129.1, 117.1, 53.6, 50.5,42.6,38.9,28.5,26.2,20.3,20.1,12.5.HRMS(ESI-TOF):exact mass calcd for C 22 H 22 N 2 NaO 6 (M+Na) + requires m/z 433.1370,found m/ z 433.1365.
实施例7Example 7
在10mL真空管中,将α-(3-苯甲酰基-5-氟)尿嘧啶取代丙烯酸甲酯1j和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环烷酮2a(0.15mmol)加至反应液中进行反应,反应0.5h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3ja,收率68%。In a 10 mL vacuum tube, α-(3-benzoyl-5-fluoro)uracil substituted methyl acrylate 1j and 1.5 eq (0.15 mmol) potassium tert-butoxide were dissolved in 1 mL of acetonitrile, and placed at -20°C for stirring and cooling After 10 minutes, α-chlorocycloalkanone 2a (0.15 mmol) was added to the reaction solution for reaction for 0.5 h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3ja was obtained by column chromatography with a yield of 68%.
实施例8Example 8
在10mL真空管中,将α-(3-苯甲酰基-5-甲基)尿嘧啶取代丙烯酸甲酯1a和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将α-氯代环己酮2b(0.15mmol)加至反应液中进行反应,反应时间为12h。TLC监测反应完全,加水淬灭,乙酸乙酯萃取。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3ab,收率66%。In a 10 mL vacuum tube, α-(3-benzoyl-5-methyl)uracil substituted methyl acrylate 1a and 1.5 eq (0.15 mmol) potassium tert-butoxide were dissolved in 1 mL of acetonitrile, and stirred at -20 °C After cooling for 10 minutes, α-chlorocyclohexanone 2b (0.15 mmol) was added to the reaction solution for reaction, and the reaction time was 12 h. The reaction was completed as monitored by TLC, quenched by adding water, and extracted with ethyl acetate. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3ab was obtained by column chromatography with a yield of 66%.
实施例9Example 9
在10mL真空管中,将α-(3-苯甲酰基-5-甲基)尿嘧啶取代丙烯酸甲酯1a和1.5eq(0.15mmol)叔丁醇钾溶于1mL乙腈,并置于-20℃搅拌冷却10分钟,然后将0.15mmolα-氯代环庚酮2c加至反应液中进行反应,反应时间为0.5h。TLC监测反应完全,将反应混合物在乙酸乙酯和水之间分配。将合并的有机相干燥,过滤并真空浓缩,得到粗油状物。然后经柱层析获得目标化合物3ac,收率72%。In a 10 mL vacuum tube, α-(3-benzoyl-5-methyl)uracil substituted methyl acrylate 1a and 1.5 eq (0.15 mmol) potassium tert-butoxide were dissolved in 1 mL of acetonitrile, and stirred at -20 °C After cooling for 10 minutes, 0.15 mmol of α-chlorocycloheptanone 2c was added to the reaction solution for reaction, and the reaction time was 0.5 h. The reaction was complete by TLC and the reaction mixture was partitioned between ethyl acetate and water. The combined organic phases were dried, filtered and concentrated in vacuo to give a crude oil. Then the target compound 3ac was obtained by column chromatography with a yield of 72%.
3ac:White solid,m.p.213.0-218.4℃;31mg,72%yield;3ac: White solid, m.p. 213.0-218.4℃; 31mg, 72% yield;
1H NMR(400MHz,CDCl3):7.87(d,J=8.0Hz,2H),7.62(t,J=7.2Hz,1H),7.48(t,J=8.0Hz,2H),7.04(s,1H),3.76(s,3H),2.82(t,J=12.0Hz,1H),2.34-2.29(m,1H),2.21-2.15(m,3H),2.00-1.73(m,8H),1.38-1.25(m,2H).13C NMR(100MHz,CDCl3):207.6,168.4,167.6,150.5,139.7,135.0,131.5,130.6,129.1,111.4,53.7,51.3,46.1,44.0,30.6,27.5,27.1,26.4,25.6,12.6.HRMS(ESI-TOF):exact mass calcd for C23H24N2NaO6(M+Na)+requires m/z 447.1527,found m/z 447.1532. 1 H NMR (400 MHz, CDCl 3 ): 7.87 (d, J=8.0 Hz, 2H), 7.62 (t, J=7.2 Hz, 1H), 7.48 (t, J=8.0 Hz, 2H), 7.04 (s, 1H), 3.76(s, 3H), 2.82(t, J=12.0Hz, 1H), 2.34-2.29(m, 1H), 2.21-2.15(m, 3H), 2.00-1.73(m, 8H), 1.38 -1.25(m, 2H). 13 C NMR (100 MHz, CDCl 3 ): 207.6, 168.4, 167.6, 150.5, 139.7, 135.0, 131.5, 130.6, 129.1, 111.4, 53.7, 51.3, 46.1, 44.0, 30.6, 27.5, 27.1,26.4,25.6,12.6.HRMS(ESI-TOF):exact mass calcd for C 23 H 24 N 2 NaO 6 (M+Na) + requires m/z 447.1527,found m/z 447.1532.
实施例10Example 10
根据实施2-9的反应条件和操作,仅改变反应底物,反应结果如下:According to the reaction conditions and operations of implementing 2-9, only the reaction substrate was changed, and the reaction results were as follows:
实施例11Example 11
在10mL真空管中,加入环丙烷化产物3aa(39.6mg,0.1mmol),并加入二氯甲烷和甲醇体积比为2:1混合溶剂1.5mL,将反应液在-20℃低温反应浴中搅拌冷却10分钟,然后称取硼氢化钠(11.3mg,0.3mmol)缓慢分批加入到反应液中,将反应液在-20℃反应30分钟。TLC检测到反应完全,向反应液中加入0.5mL饱和氯化铵溶液淬灭反应,然后加入二氯甲烷和水进行萃取,柱层析法对产物进行分离纯化,最终得到酮羰基还原产物4aa(24mg,0.06mmol)。In a 10 mL vacuum tube, the cyclopropanation product 3aa (39.6 mg, 0.1 mmol) was added, and 1.5 mL of a mixed solvent of dichloromethane and methanol with a volume ratio of 2:1 was added, and the reaction solution was stirred and cooled in a low temperature reaction bath of -20 °C After 10 minutes, sodium borohydride (11.3 mg, 0.3 mmol) was weighed and slowly added to the reaction solution in batches, and the reaction solution was reacted at -20° C. for 30 minutes. TLC detected that the reaction was complete, 0.5 mL of saturated ammonium chloride solution was added to the reaction solution to quench the reaction, and then dichloromethane and water were added for extraction, and the product was separated and purified by column chromatography to finally obtain the ketone carbonyl reduction product 4aa ( 24 mg, 0.06 mmol).
4aa:White solid,m.p.175.5-180.1℃;24mg,60%yield;4aa: White solid, m.p.175.5-180.1℃; 24mg, 60% yield;
1H NMR(400MHz,CDCl3):7.97-7.95(m,2H),7.66-7.63(m,1H),7.50(t,J=8.0Hz,2H),7.13(s,1H),3.74(s,3H),3.54(d,J=3.2Hz,1H),2.30(s,1H),2.13-2.02(m,1H),1.99-1.94(m,3H),1.90-1.70(m,6H),1.34(d,J=5.2Hz,1H).13C NMR(150MHz,CDCl3):169.2,167.8,153.5,139.8,135.3,131.2,130.5,129.3,112.8,77.4,53.3,49.8,47.0,32.9,27.9,26.6,20.9,12.6.HRMS(ESI-TOF):exact mass calcd for C21H22N2NaO6(M+Na)+requires m/z 421.1370,found m/z 421.1366. 1 H NMR (400 MHz, CDCl 3 ): 7.97-7.95 (m, 2H), 7.66-7.63 (m, 1H), 7.50 (t, J=8.0 Hz, 2H), 7.13 (s, 1H), 3.74 (s ,3H),3.54(d,J=3.2Hz,1H),2.30(s,1H),2.13-2.02(m,1H),1.99-1.94(m,3H),1.90-1.70(m,6H), 1.34 (d, J=5.2 Hz, 1H). 13 C NMR (150 MHz, CDCl 3 ): 169.2, 167.8, 153.5, 139.8, 135.3, 131.2, 130.5, 129.3, 112.8, 77.4, 53.3, 49.8, 47.0, 32.9, 27.9,26.6,20.9,12.6.HRMS(ESI-TOF):exact mass calcd for C 21 H 22 N 2 NaO 6 (M+Na) + requires m/z 421.1370,found m/z 421.1366.
实施例12Example 12
在10mL真空管中,准确称量4aa(39.8mg,0.1mmol)加入到反应管中,然后塞上橡胶塞并使用封口膜密封,进行氮气交换以保证反应可以在氮气氛围下进行,用针管吸取氨/甲醇溶液(浓度为1mol/L)1mL加入到反应管中,将反应液在室温下进行反应,反应时间为3小时,TLC检测到反应完全,将反应液减压蒸发然后通过柱层析法对产物进行分离纯化,最终得到产物5aa(24mg,0.08mmol)。In a 10mL vacuum tube, accurately weigh 4aa (39.8mg, 0.1mmol) into the reaction tube, then plug it with a rubber stopper and seal it with parafilm, and perform nitrogen exchange to ensure that the reaction can be carried out in a nitrogen atmosphere. Use a syringe to absorb ammonia 1 mL of methanol solution (concentration of 1 mol/L) was added to the reaction tube, and the reaction solution was reacted at room temperature for 3 hours. TLC detected that the reaction was complete. The reaction solution was evaporated under reduced pressure and then passed through column chromatography. The product was isolated and purified to finally obtain product 5aa (24 mg, 0.08 mmol).
代表性化合物表征数据如下:Representative compound characterization data are as follows:
5aa:White solid,m.p.233.0-238.4℃;26mg,87%yield;5aa: White solid, m.p.233.0-238.4℃; 26mg, 87% yield;
1H NMR(400MHz,CDCl3):9.36(s,1H),7.00(s,1H),4.23(s,1H),3.71(s,3H),3.52(d,J=3.2Hz,1H),2.38(s,1H),2.11(s,1H),1.95-1.72(m,8H),1.69(d,J=5.3Hz,1H),1.27(d,J=5.2Hz,1H).13CNMR(150MHz,CDCl3):169.4,163.4,154.3,140.1,112.7,77.2,53.3,49.3,47.0,32.8,27.9,26.9,20.9,12.5.HRMS(ESI-TOF):exact mass calcd forC14H18N2NaO5(M+Na)+requires m/z 317.1108,found m/z 317.1107. 1 H NMR (400MHz, CDCl 3 ): 9.36(s,1H), 7.00(s,1H), 4.23(s,1H), 3.71(s,3H), 3.52(d, J=3.2Hz,1H), 2.38(s, 1H), 2.11(s, 1H), 1.95-1.72(m, 8H), 1.69(d, J=5.3Hz, 1H), 1.27(d, J=5.2Hz, 1H). 13 CNMR( 150MHz, CDCl 3 ): 169.4, 163.4, 154.3, 140.1, 112.7, 77.2, 53.3, 49.3, 47.0, 32.8, 27.9, 26.9, 20.9, 12.5.HRMS(ESI-TOF): exact mass calcd forC 14 H 18 N 2 NaO 5 (M+Na) + requires m/z 317.1108, found m/z 317.1107.
以上实施例描述了本发明的基本原理、主要特征及优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书的描述的只是说本发明的原理,在不脱离本发明原理的范围下,本发明还会有各种变化和改进,这些变化和改进均落入本发明保护的范围内。The above embodiments describe the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited by the above-mentioned embodiments. The descriptions of the above-mentioned embodiments and the description only describe the principles of the present invention. Without departing from the scope of the principles of the present invention, there are various Variations and improvements all fall within the scope of the present invention.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910374991.2A CN110015996B (en) | 2019-05-07 | 2019-05-07 | Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910374991.2A CN110015996B (en) | 2019-05-07 | 2019-05-07 | Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110015996A CN110015996A (en) | 2019-07-16 |
CN110015996B true CN110015996B (en) | 2020-07-28 |
Family
ID=67193261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910374991.2A Active CN110015996B (en) | 2019-05-07 | 2019-05-07 | Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110015996B (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107602559B (en) * | 2017-09-29 | 2019-10-18 | 河南师范大学 | A method for the synthesis of chiral three-membered carbocyclic nucleosides by asymmetric cyclopropanation initiated by Michael addition |
CN108314655B (en) * | 2018-03-29 | 2021-01-15 | 河南师范大学 | A kind of method for synthesizing three-membered carbocyclic pyrimidine nucleoside analogs by rhodium-catalyzed asymmetric cyclopropanation |
-
2019
- 2019-05-07 CN CN201910374991.2A patent/CN110015996B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN110015996A (en) | 2019-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108314658A (en) | A kind of preparation method of Duo substituted oxazoles derivative | |
CA2960473A1 (en) | Processes for the preparation of tadalafil and intermediates thereof | |
CN110015996B (en) | Method for synthesizing 2' -spiro-substituted ternary carbocyclic nucleoside | |
CN111995565A (en) | A kind of preparation method of (S)-2-piperidinecarboxylic acid | |
JPH0670049B2 (en) | Method for N-alkylation of dihydrolysergic acid | |
JPS6247190B2 (en) | ||
WO1996026181A1 (en) | Aminotetralone derivatives and process for producing the same | |
Demopoulos et al. | Synthesis of 6, 7, 8, 9‐tetrahydro‐N, N‐di‐n‐propyl‐1H‐benz [g] indol‐7‐amine, a potential dopamine receptor agonist | |
CN111087405B (en) | A kind of method for asymmetric synthesis of amaryllidaceae alkaloid (+)-γ-lycorane | |
CN112142664A (en) | A kind of synthetic method of polysubstituted naphthoazepine heterocyclic compounds | |
CN101454276A (en) | Method for the production of 8-aryl-octanoyl derivatives | |
CN115611894B (en) | A nitrogen-containing spirocyclic compound or a pharmaceutically acceptable salt thereof and a preparation method and application thereof | |
CN108358780B (en) | Method for synthesizing highly diastereoselective α-acyl-oxygenated cyclic ketones | |
CN103936753B (en) | Natural products Daldinin and the like total synthesis method | |
CN115819208B (en) | A kind of synthesis method of 2-aryl-3,4-dihydro-1(2H)-naphthone compounds | |
JP2007051128A (en) | Method for producing aniline having aralkyloxy or heteroaralkyloxy group | |
CN113200902B (en) | Polysubstituted pyrrole derivative and preparation method thereof | |
CN110650735A (en) | Highly diastereoselective structures of 4, 5-spirocycles by palladium-catalyzed intramolecular alkenylation | |
Gonnot et al. | Expedient synthesis of mequitazine an antihistaminic drug by palladium catalyzed allylic alkylation of sodium phenothiazinate | |
CN110963959B (en) | Preparation method for synthesizing N-protected and unprotected 3-hydroxy-4, 4-dimethylpiperidine | |
CN100451010C (en) | Method for synthesizing (R)-3-amido tetrahydrofuran | |
Leeson et al. | Transannular reactions of 5-azido-and 5-nitronodibenzo [a, e] cyclooctatrienes and-dibenzo [a, d] cycloheptatrienes. Syntheses of pavine and homoisopavine analogs | |
CN117924283A (en) | Intermediate spiro compound and preparation method thereof | |
JP4937442B2 (en) | Process for producing 5-fluorooxindole | |
CN115819492A (en) | C14 substituted steroid and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |